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Purpose: Two phase II clinical trials in the aerodigestive tumors
were undertaken to evaluate the efficacy of imatinib mesylate-
docetaxel. We hypothesized that imatinib mesylate would inhibit
platelet-derived growth factor receptor (PDGFR) on pericytes
and increase docetaxel uptake into tumor cells for an additive
antitumor effect. Baseline tumor specimens, serum, and perfusion
computed tomography (CT) scans were obtained for supportive
evaluation.
Materials and Methods: Eligible patients with metastatic non-
small cell lung cancer (NSCLC) treated with 1 prior therapy and
chemonaive patients with head and neck squamous cell carcinoma
(HNSCC) were enrolled in separate trials, which administered both
docetaxel (60 mg/m2 every 3 weeks) and oral imatinib mesylate
(400 mg daily). Both trials used interim analyses for efficacy and
safety.
Results: Twenty-two patients with NSCLC and seven patients with
HNSCC were enrolled. Both trials were closed early due to lack of
efficacy, significant toxicity, and a potential antagonistic effect. In
the NSCLC study, the response rate was 4.5%, median progression-
free survival (PFS) 7.9 weeks, and overall survival 35.6 weeks. The
HNSCC trial yielded a response rate 0%, PFS 8.8 weeks, and overall
survival 34.7 weeks. Baseline NSCLC tumor immunohistochemical
biomarker analyses indicated that lower expression of stromal
PDGFR correlated with a better PFS, whereas stromal PDGFR
and tumor cell PDGFR were associated with a worse clinical
outcome when treated with imatinib mesylate-docetaxel.
Conclusion: We do not recommend further investigation of this
regimen in the aerodigestive tumors. Future investigations in
PDGFR tyrosine kinase inhibitors should be used with caution in
combination with taxanes and validation of the potential predictive
or prognostic biomarkers stromal PDGFR/, and tumor cell
PDGFR are needed.
Key Words: Imatinib mesylate, Docetaxel, Non-small cell lung
cancer, Head and neck squamous cell carcinoma.
(J Thorac Oncol. 2011;6: 2104–2111)
Platelet-derived growth factor (PDGF) and PDGF receptor(PDGFR) are coexpressed in many human cancers and
initiate signaling cascades (i.e., c-Src, phospholipase C-,
PI3K-AKT-mTor, and Grb2/Sos) that ultimately lead to cell
growth, alterations in cell morphology, and inhibition of
apoptosis.1 PDGFR also affects drug transport through reg-
ulation of tumor interstitial fluid pressure (IFP)1,2 where
inhibition of PDGFR decreases tumor IFP and increases
tumor chemotherapy uptake for a potential additive antitumor
effect.3,4 Specifically, Pietras et al.5 showed in murine xeno-
graft models that imatinib mesylate (Novartis Pharma AG,
Basel, Switzerland) combined with paclitaxel had a syn-
ergistic antitumor effect. Additional murine studies report
that taxanes increase tumor vessels’ diameter, promote
blood perfusion, and thus enhance drug delivery into
tumors.6 Docetaxel, a diterpenoid taxane, is highly active
in both non-small cell lung cancer (NSCLC) and head and
neck squamous cell carcinoma (HNSCC).7,8 In platinum-
refractory NSCLC, docetaxel has a 7 to 10% response rate
(RR)9,10 and in head and neck squamous cell carcinoma
(HNSCC) has RRs of 35% (range: 24–45%) as a single
agent.11–13
We hypothesized that imatinib mesylate would poten-
tiate the activity of docetaxel in platinum-refractory NSCLC
and HNSCC by facilitating delivery of docetaxel to the tumor
through a reduction in IFP by PDGFR inhibition. A prior
phase I trial in prostate cancer demonstrated the feasibility of
combining these two agents and found minimal overlapping
toxicity.14 Therefore, two separate phase II single-arm trials
in platinum-refractory NSCLC and chemonaive HNSCC
were conducted.
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PATIENTS AND TRANSLATIONAL METHODS
In protocol 2004-0726, eligible patients had metastatic
NSCLC, one prior platinum-based therapy; age 18 years;
Eastern Cooperative Oncology Group performance status 0
to 2; life expectancy  6 months; and adequate organ
function. In protocol 2006-0362, eligible patients had
metastatic HNSCC (excluding nasopharynx), chemonaive,
and nonradiated measurable disease. Prior induction or
adjuvant chemotherapy or chemoradiotherapy with cura-
tive intent was allowed. In both trials, docetaxel (60 mg/m2
every 3 weeks) and oral imatinib mesylate (400 mg daily)
were initiated on day 1, as adapted from a prior phase I
trial.14 Response was assessed by the original RECIST
criteria published in 2000.15
For the statistical design of both studies, the primary
end point was to determine the RR of imatinib mesylate-
docetaxel, and secondary objectives were safety/tolerability,
progression-free survival (PFS), and overall survival (OS).
Exploratory objectives included perfusion computed tomog-
raphy (CT) scan measurements, serum, and tumor tissue
assessment for potential biomarkers. An early stopping rule
for futility was incorporated into both studies. Analyses of the
survival and tumor biomarkers used Kaplan-Meier method,
Pearson or Spearman rank correlation coefficients for contin-
uous biomarkers, 2 or Fisher’s exact test for discrete bio-
markers, and McNemar’s test evaluated change of a single
discrete biomarker over time. The Cox models were used to
estimate the effect of biomarkers and other covariates on
survival.
For patients with amenable tumors, standard tumor
perfusion protocols were used at baseline and after cycle 1
and used CT perfusion software (GEMS, Milwaukee, WI) to
assess blood flow and volume. Optional blood specimens
were collected at baseline, week 3, week 6, and off study.
PDGF-BB concentrations were determined using Human
PDGF-BB Quantikine Immunoassay (R&D Systems, Inc,
Minneapolis, MN). Retrospectively, baseline tumor speci-
mens were collected for biomarker analyses using standard
immunohistochemical (IHC)16 and fluorescent in situ hybrid-
ization (FISH).17 IHC included PDGFR (Cell Signaling
Technology, Danvers, MA), phosphorylated-PDGFR (p-
PDGFR, Tyr1021), and PDGFR (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA). Cytoplasmic or stromal expres-
sion was quantified using intensity scores (0, none; 1, weak;
2, moderate; and 3, strong) and percentage (0–100%) of
the extent of reactivity. Final expression scores (0–300) were
obtained by multiplying the intensity and reactivity extension
values. PDGFRB gene copy number was assessed using a
dual-color FISH assay (Abbott Molecular, IL) prepared from
Vysis SpectrumOrange LSI CSF1R probe (5q33-34) and
reference probe Vysis SpectrumGreen LSI D5S23: D5S721
as an internal control. PDGFRB gene copy number was
evaluated in two ways as per standard protocol: (a) gene
amplification, defined as presence of loose or tight gene
clusters or PDGFRB gene to centromeric probe 5 ratio 2
and (b) copy number gain, defined as 4 copies in 40%
cells or presence of gene amplification.17
RESULTS
NSCLC Protocol 2004-0726
Twenty-two patients were enrolled (February 2005–
October 2006), and demographics are listed in Table 1. The
median number of cycles of docetaxel was 2 (range: 1–6),
with two patients requiring dose reductions to 45 mg/m2 after
cycles 1 and 4, respectively. The median number of cycles of
imatinib mesylate was 2 (range: 1–6) with a compliance rate
of 94.4%.
The main adverse events (Table 2) were grades 1 to 2
fatigue, diarrhea, neuropathy, edema, and nausea/vomiting.
Grade 3 toxicities included dyspnea, fatigue, and edema.
Seven patients experienced at least one grade 3 adverse event,
and 10 patients experienced at least one grade 2 adverse
event. No grade 4 or 5 toxicities were reported.
Two patients were not evaluable for efficacy due to
grade 3 toxicity after cycle 1. In the intent to treat analyses,
the overall RR was 4.5%. Two additional patients had minor
responses (MRs), and six patients had stable disease (SD).
The overall disease control rate was 40.9%. The three patients
with a minor or partial response had response durations of
TABLE 1. Patient Demographics from Two Phase II Trials in
Salvage NSCLC (Protocol 2004-0726) and Chemonaïve
HNSCC (Protocol 2006-0362)
Characteristics
NSCLC
(n  22)
HNSCC
(n  6)
Age (yr)
Median (range) 64 (45–75) 64 (44–75)
Gender
Male 13 4
Female 9 2
Ethnicity
African American 1 0
White 21 6
Hispanic 0 0
Asian 0 0
Performance status
0 4 2
1 16 4
2 2 0
Histology
Adenocarcinoma 10 0
Squamous cell carcinoma 4 6
Neuroendocrine 1 0
Sarcomatoid NSCLC 2 0
NSCLC NOS 5 0
Smoking status
Never 2 1
Former 8 2
Current 12 3
Presence of brain metastases
Yes 2 0
No 20 6
NOS, not otherwise specified; NSCLC, non-small cell lung cancer; HNSCC, head
and neck squamous cell carcinoma.
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158.6, 22, and 40.3 weeks, respectively. In patients with a
response or SD, the median time to progression (TTP) was 17
weeks. The follow-up time was 36 weeks for all evaluable
patients, median PFS was 7.9 weeks, and OS was 35.6 weeks.
Based on univariate analyses, none of the patient or tumor
characteristics predicted for RR, PFS, or OS. Because of the
low RR, the trial was terminated early during the interim
analyses as detailed in the statistical design.
Only five patients (three PD and two SD) consented for
baseline serum PDGF levels. There was no association of
PDGF serum level with response to therapy, survival, or
development of adverse events. Of the IHC biomarkers,
adequate tumor tissue was available from 13 patients for
stromal PDGFR, tumor cell PDGFR,, and tumor cell
p-PDGFR expression; 10 patients had available tissue for
PDGFR and p-PDGFR expression in the stroma. A Spear-
man correlation identified that patients with higher PDGFR
IHC expression in the stroma were also likely to have higher
PDGFR IHC expression in tumor cell cytoplasm (p 
0.045). Also, patients with higher PDGFR IHC expression
in tumor cells were more likely to have p-PDGFR in the
tumor cell cytoplasm (p  0.007). Current smokers did have
had higher levels of PDGFR IHC expression in the stroma
compared with former/never smokers (p  0.03). There was
no other statistically significant association of any of the
biomarkers with either patient demographics or RR.
Patients with lower stromal PDGFR IHC expression
had a trend toward improved disease control (p 0.08) when
treated with imatinib mesylate-docetaxel. When the bio-
marker IHC scores were dichotomized, any baseline expres-
sion of PDGFR in the stroma (p  0.04) or any PDGFR
expression (p  0.03) in the tumor cytoplasm were both
associated with a worse PFS, whereas lower expression of
PDGFR in the stroma correlated to a better PFS (p  0.03)
(Figures 1A–C). Analysis of OS by dichotomized IHC scores
indicated a trend toward a worse OS if positive for any
PDGFR expression in the stroma (Figure 1D).
PDGFRB gene copy number was analyzed in 13 avail-
able baseline NSCLC tumor specimens, but only one patient
had increased gene copy number. This patient had adenocar-
cinoma and had rapid progression of disease after only one
cycle of therapy. No correlation of PDGFRB gene copy
number to PDGFR IHC could be made due to the limited
numbers. There was no correlation of PDGFRB increased
gene copy number to survival or RR.
Baseline and postcycle 1 therapy perfusion CT scans
were conducted successfully on two patients. The first patient
had an increase in baseline blood flow but decrease in blood
volume after one cycle of combined therapy (Figures 2A–F).
After two cycles of therapy, this patient had SD, although
some central necrosis was noted in the middle of the tumor.
Because of severe nausea, this patient became noncompliant
and was taken off study. The second patient had a decrease in
blood flow and blood volume (Figures 3A–F) and had an MR
after two cycles of therapy but was removed from the study
after she developed pneumonia and was unable to continue
imatinib mesylate.
HNSCC Protocol 2006-0362
Six patients were enrolled (January–October 2007), and
one patient was inevaluable for response due to intolerance
after one cycle of therapy (Table 1). The median number of
cycles of both docetaxel and imatinib mesylate was 2 (range:
1–6), with one docetaxel dose reduction to 45 mg/m2 during
cycle 6. Patient compliance with the imatinib mesylate was 98.9%.
The main adverse events reported were grades 1 to 2
fatigue, nausea, anemia, alopecia, and electrolyte abnormal-
ities (Table 2). All patients on the study experienced at least
one grade 3 adverse event, which included anemia, dyspha-
gia, thrombocytopenia, and neutropenic fever. No grade 4 or
5 toxicities were reported.
In the intent to treat analyses, the overall RR was 0%.
Two patients had SD as their best response for a disease
control rate of 28.6%. In the patients with SD, the median
TTP was 15 weeks. After a median follow-up time of 11.5
weeks for all evaluable patients, the median PFS was 8.8
weeks and OS was 34.7 weeks. Based on univariate analyses,
none of the patient or tumor characteristics predicted for PFS
or OS. Because of the 0% RR and high rate of adverse events,
the trial was terminated early during the interim analyses as
detailed in the statistical design.
Only two patients (SD) from 2006-0362 consented for
use of their blood for baseline serum PDGF levels. There was
no association of PDGF serum level with response to therapy,
survival, or development of adverse events. After pooling the
serum specimens from 2004-0726 and 2006-0362 analyses,
baseline PDGF was not associated with either PFS or OS.
Four patients (one SD, two PD, and one inevaluable) had
tumor specimens available for biomarker analyses and three
for PDGFRB gene copy number analysis. One of the three
TABLE 2. Summary of Treatment-Related Events from the
Combination of Imatinib Mesylate and Docetaxel in
Protocols 2004-0726 (Salvage NSCLC) and 2006-0362
(Chemonaïve HNSCC)
Toxicity
2004-0726
NSCLC,
Grade
2006-0362
HNSCC,
Grade
1–2 3 4 5 1–2 3 4 5
Alopecia 6 0 0 0 5 0 0 0
Anemia 1 0 0 0 5 3 0 0
Diarrhea 13 0 0 0 3 0 0 0
Dyspnea 6 8 0 0 0 0 0 0
Dysphagia 0 0 0 0 2 2 0 0
Edema (limb and facial) 15 3 0 0 3 0 0 0
Fatigue 17 3 0 0 7 1 0 0
Hypokalemia 0 0 0 0 4 1 0 0
Hypomagnesemia 0 0 0 0 4 0 0 0
Nausea 7 1 0 0 6 1 0 0
Neuropathy 10 1 0 0 0 0 0 0
Nonneutropenic fever 1 0 0 0 1 1 0 0
Neutropenic fever 0 0 0 0 0 2 0 0
Thrombocytopenia 0 1 0 0 0 2 0 0
Vomiting 2 1 0 0 1 0 0 0
NSCLC, non-small cell lung cancer; HNSCC, head and neck squamous cell
carcinoma.
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patients had an increased PDGFRB gene copy number and
had SD for four cycles of therapy. Based on the sample size,
statistical analyses could not be conducted.
DISCUSSION
Despite promising preclinical activity,5,18–23 our two
phase II trials showed a high intolerance of imatinib mesy-
late-docetaxel and a lack of evidence of additive clinical
efficacy. Patients in both trials reported significant fatigue,
diarrhea, nausea/vomiting, and edema; and this relative intol-
erance has been witnessed in other trials using this regimen,
albeit different docetaxel schedules.24–27 Yardley et al.25
reported withdrawal of 7 of the first 15 patients with meta-
static breast cancer from a similar regimen due to gastroin-
testinal side effects.25 As both of our phase II trials were
terminated early, we do not recommend further investigation
of this combination due to concerns of a potential antagonis-
tic effect between the agents. This lack of clinical benefit and
potential antagonism can be seen consistently across other
solid tumor clinical trials24–26 using the combination regimen
(Table 3). For example, our second-line NSCLC study had a
lower RR 4.5% and median PFS 2 months, when compared
with RR 8.8% and PFS 2.9 months from a prior second-line
docetaxel monotherapy NSCLC study.28 Our results mirror a
recently published phase II trial29 using imatinib mesylate
(600 mg daily) and weekly docetaxel (30 mg/m2) where the RR
was 5.5% and median TTP 1.9 months. In metastatic HNSCC,
docetaxel is usually one of the most active agents,11–13,30 but our
trial had a 0% RR and median PFS of 2 months.
Proposed Mechanisms of Resistance
and Antagonism
It is unclear why the combination of imatinib-docetaxel
would lead to a worse clinical outcome than expected with
FIGURE 1. Survival curves for biomarker analyses from protocol 2004-0726. A–C, Immunohistochemical (IHC) expression lev-
els of tumor tissue biomarkers by progression-free survival (PFS). A, A significant improvement in PFS when comparing any
baseline IHC expression of platelet-derived growth factor receptor (PDGFR) in the stroma to no IHC expression (p  0.04)
and in (B), any baseline IHC expression of PDGFR in the tumor cell cytoplasm to no IHC expression (p  0.03). C, Compari-
son of low IHC expression of PDGFR in the stroma (10 score) with high IHC expression (10) by PFS (p  0.03). D, The
overall survival results by any or no IHC expression of PDGFR in the stromal tissue.
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docetaxel alone. The following are proposed hypotheses
based on the current literature. First, antagonism between
imatinib and docetaxel may occur because imatinib mesylate
may arrest tumor cells at the G0–G1 checkpoint through
inhibition of PDGFR and the downstream PI3K/AKT path-
way31; this may compromise the antitumor effects of do-
cetaxel, which works during M phase.32,33 Second, p-glyco-
protein (MDR-1), an ATP-binding cassette (ABC) transport
protein B1, has both docetaxel and imatinib as substrates and
is implicated in resistance to both agents.34,35 The ABCB1
gene is strongly induced by docetaxel in resistant A549 cell
lines35 possibly through activation of pregnane X receptor
pathway36; and imatinib resistance has also been linked to
ABCB1 induction in leukemic cell lines.37 An interesting
finding was recently reported by Burger et al.38 who demon-
strated that in vitro continuous exposure (100 days) to
imatinib increases gene expression of ABCG2 and ABCB1
and up-regulates the drug transporter-mediated efflux. As
these transporters are normally expressed in the gastrointes-
tinal tract,39–41 it is possible that reduced bioavailability of
both docetaxel and imatinib may occur when coadministered,
as imatinib is administered orally and docetaxel has entero-
hepatic recirculation.40 This may partially explain why the
promising efficacy results from murine xenograft models2,42
FIGURE 2. Perfusion computed tomography (CT) scan re-
sults on a 63-year-old man with metastatic non-small cell
lung cancer (NSCLC). Baseline contrast-enhanced chest CT
(A) at the level of the pulmonary trunk (P) demonstrates a
3.5 cm primary right upper lobe lung cancer (arrowhead).
One month later, after one cycle of imatinib mesylate-do-
cetaxel was administered, a contrast-enhanced chest CT
shows no significant anatomic change in size, but central
tumor cavitation was observed (B, arrow). Baseline CT blood
flow (C) was 72.3 ml/min/g and increased 10% on the post-
cycle 1 perfusion CT scan (D) to 80.4 ml/min/g. Blood vol-
ume at baseline (E) was 2.6 ml/g and decreased 7% to 2.4
ml/g on the postcycle 1 perfusion CT scan (F). This patient
had toxicity with the regimen and was removed from the
study after cycle 2 of treatment. By RECIST, the patient had
stable disease after two cycles of therapy for imatinib mesy-
late-docetaxel.
FIGURE 3. Perfusion computed tomography (CT) scan re-
sults on a 43-year-old woman with metastatic non-small cell
lung cancer (NSCLC). Baseline contrast-enhanced chest CT
(A) demonstrates the primary lung cancer (arrow). After 1
cycle of imatinib mesylate-docetaxel was administered, a
contrast-enhanced chest CT (B) shows no significant change
in anatomic size. Baseline CT blood flow (C) was 13.5 ml/
min/g, which decreased 9% on the postcycle 1 perfusion CT
scan (D) to 12.3 ml/min/g. Blood volume at baseline (E) was
3.2 ml/g and decreased 16% to 2.7 ml/g on the postcycle 1
perfusion CT scan (F). This patient developed a minor re-
sponse after cycle 2 of therapy but developed pneumonia
during that time and was unable to continue on the ima-
tinib mesylate for cycle 3 of therapy and was removed from
the study.
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with imatinib-docetaxel failed to translate into human trials,
as imatinib was only administered for short periods of time in
the laboratory. Additional supporting evidence for this hy-
pothesis is found in a recent clinical trial where Kelly et al.34
evaluated the combination of docetaxel and tariquidar, a
p-glycoprotein antagonist, in patients with lung, ovarian, and
cervical cancer. In 8 of 10 patients with NSCLC, an increase
in 99Tc-sestamibi uptake (a surrogate marker for drug accu-
mulation) was seen with the combination regimen and is
suggestive that inhibition of p-glycoprotein would increase
both imatinib and docetaxel uptake into tumor cells.34
Finally, an autocrine loop mechanism with the PDGF/
PDGFR pathway exists, and inhibition of PDGFR may cause
a subsequent rise in ligand PDGF-BB, which potentially
stimulates increased tumor cell proliferation by alternate
pathways. McCarty et al.43 demonstrated in gastrointestinal
tumors that PDGF-BB overexpression increased pericyte
coverage of endothelial cells and led to a decrease in tumor
cell proliferation. When treated with imatinib, these tumor
cells which overexpressed PDGF-BB actually had an increase
in tumor cell proliferation and decreased number of peri-
cytes.43 These data support the observation of a worse clinical
outcome associated with the rise in serum PDGF from the
prostate cancer studies.24,44 Mathew et al.24 reported that
patients with prostate cancer who received imatinib mesylate-
docetaxel had a worse clinical response by PSA (p  0.001)
and shorter PFS (p  0.032) if they had a greater drop in
p-PDGFR levels in peripheral blood leukocytes after one
cycle of imatinib-docetaxel treatment. A subsequent detailed
analysis44 from the study suggested that dephosphorylation of
peripheral blood leukocyte p-PDGFR correlated with a rise in
serum PDGF (suggesting a compensatory rise in ligand) and
was associated with worse PFS and OS, regardless of whether
the patients received docetaxel alone or with imatinib. This
TABLE 3. Summary of Selected Solid Tumor Clinical Trials Using Imatinib Mesylate Combined with Docetaxel
Authors Trial Phase
Dose of
Imatinib
Added to
Docetaxel Tumor Type N Response Rate
Median
PFS (mo)
Median OS
(mo) Toxicity
Mathew
et al.16
I 600 mg Androgen-
independent
prostate cancer
28 24% had 50%
reduction in
serum PSA
11 NR 35% fatigue and 20%
nausea
Mathew
et al.26
II randomized Arm A: 600 mg Castration-resistant
prostate cancer
with bone
metastases
116 Arm A 8% Arm A: 4.2 Arm A: 20.9 Lack of efficacy and excess
grade 3 fatigue and
nausea led to early trial
termination.
Arm B: placebo Arm A  57 Arm B 13% Arm B: 4.2 Arm B: not
attained
Arm B  59
Coleman
et al.29
II 600 mg Pretreated
refractory
ovarian and
primary
peritoneal
cancers
16 0% ORR NR NR 34% fatigue
31% nausea/vomiting
4 patients inevaluable due
to toxicity in cycle 1 of
therapy; trial closed early
due to lack of clinical
response.
Matei
et al.28
II 600 mg Pretreated
platinum-
resistant ovarian
and primary
peritoneal
carcinomatosis
23 21.7% ORR 1.8 9.56 5 patients removed from
study due to toxicity.
For grades 1–2: 83%
fatigue, 74% nausea,
61% diarrhea, 65%
edema; regimen not
studied further due to
lack of efficacy
Yardley
et al.27
II 600 mg, 400
mg
Metastatic breast
cancer
37 16% ORR 9.3 15.4 Trial halted early due to
poor tolerance and lack
of efficacy. Close to half
of the patients withdrew
from the study.
Huang
et al.31
II 600 mg weekly
docetaxel
NSCLC 23 5.5% ORR TTP 1.9 6.1 Trial stopped at interim
analysis due to lack of
efficacy.
Tsao et al.
(current
trial)
II 400 mg NSCLC 22 4.5% ORR 2 8.9 Trial halted early due to
lack of efficacy and poor
tolerance.
Tsao et al.
(current
trial)
II 400 mg HNSCC 6 0% ORR 2.2 8.7 Trial halted early due to
lack of efficacy and poor
tolerance.
N, number of patients; ORR, overall response rate (CR  PR); TTP, time to progression; PFS, progression-free survival; OS, overall survival; NR, not reported; NSCLC,
non-small cell lung cancer; HNSCC, head and neck squamous cell carcinoma.
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implies that elevation of serum PDGF and decreased phos-
phorylation of PDGFR in peripheral leukocytes may predict
for resistance to docetaxel therapy.44 For the plasma PDGF
levels in our trials, based on the seven patients with sufficient
specimens, there was no correlation of baseline levels or
subsequent serial levels with response or survival. Neverthe-
less, because of our small numbers of paired specimens, we
were unable to confirm the results reported by Mathew et al.44
Translational Correlates
For our additional translational correlates in the two
trials, we attempted to conduct perfusion CT scans to assess
changes in tumor blood volume/flow after PDGFR inhibi-
tion.3,5 Unfortunately, only a minority of patients were suit-
able candidates for perfusion CT scans as perfusion is diffi-
cult to assess accurately in peripheral lung tumors (due to
respiratory motion artifact). Both patients with successful
matched pre- and posttherapy perfusion scans did show a
decrease in intratumoral blood volume, but only one patient
also had a decrease in intratumoral blood flow. The patient
with both a drop in blood volume and flow had an MR to two
cycles of therapy, whereas the other patient had SD.
With respect to tissue biomarkers, we also failed to
prove our initial hypothesis that patients with positive IHC
expression of PDGFR and  would respond more favorably
to imatinib PDGFR inhibition and docetaxel therapy. Instead,
we discovered that higher stromal IHC PDGFR and any
stromal IHC expression of PDGFR or tumor cell PDGFR
correlated with a worse PFS. Also, patients with PDGFR
stromal IHC expression had a trend toward a worse OS.
PDGFR FISH had no predictive value. Our IHC biomarker
results stand in contrast to the findings in Huang et al.29 (n 
15 NSCLC tumors treated with imatinib-docetaxel) where
two of the four patients with SD had high tumor cell
PDGFR expression and the one responder had 1 tumor
cell IHC PDGFR expression. In our NSCLC trial, only two
patients had tumor cell IHC expression of PDGFR, and
therefore, our analysis of tumor cell PDGFR as a predictive
biomarker to this regimen is limited. It is also unclear
whether PDGFR expression on tumor cells is prognostic of
a more aggressive clinical phenotype; Donnem et al.45 iden-
tified high tumor cell PDGFR as a negative prognostic
factor after surgery for disease-free survival. In addition,
tumor cell expression of PDGF-A was associated with greater
lymph node metastases, which is suggestive of a paracrine
effect on PDGFR expressing endothelial cells.46
Based on our two phase II trials and on previous
publications, it is not feasible to draw any definitive conclu-
sions on whether PDGFR and  IHC in either tumor or
stroma are negative prognostic or predictive biomarkers for
chemotherapy resistance; but future studies may be able to
elaborate on the biology. This may be a critical area to
explore in future investigations of PDGFR tyrosine kinase
inhibitors as the unique roles of PDGFR/ signaling and the
potential differential effect of tyrosine kinase inhibition on
the receptor isoforms is presently unknown in NSCLC and
may have clinical significance. In murine embryonic fibro-
blast cell lines with knockout PDGFR isoforms, Wu et al.47
explored the divergent contributions of PDGFR and
PDGFR by gene expression arrays (with and without ima-
tinib mesylate inhibition) and identified 33 gene sets activated
by PDGFR and 15 gene sets by PDGFR. More specifi-
cally, PDGFR activated the angiogenic and epidermal
growth factor receptor pathways, whereas PDGFR activated
C21-steroid hormone biosynthesis. In imatinib mesylate-
treated cells, inhibition of PDGFR led to inhibition of ERK
activation, whereas AKT signaling was blocked with inhibi-
tion of either PDGFR or . This preclinical study provides
supportive evidence to the results of our trial that the different
PDGFR isoforms regulate distinct signaling pathways and
their pattern of expression in tumors and stroma may have
important clinical relevance when using specific tyrosine
kinase inhibitors.
CONCLUSION
The regimen of imatinib mesylate combined with do-
cetaxel was not efficacious or tolerated in the pretreated lung
or chemonaive HNSCC cancer populations. Both our phase II
trials were terminated early, and there is suggestion that an
antagonistic effect may be present with coadministration of
these two agents. We do not recommend further study of this
regimen in these populations. For future studies using
PDGFR tyrosine kinase inhibitors, examination of potential
positive predictive biomarkers such as lower stromal IHC
expression of PDGFR and negative predictive biomarkers
such as stromal IHC expression of PDGFR and tumor cell
IHC expression of PDGFR should be considered.
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